Novo Nordisk Is Cheaper Than Lilly. This Week’s Data Explains Why That Could Be a Mistake.

Investors who want obesity exposure have spent the past year rewarding Eli Lilly and penalizing Novo Nordisk. Over the past year, LLY is up sharply while NVO is down materially. The valuation gap has followed: Lilly now trades at a mid-40s trailing price-to-earnings multiple, while Novo sits around 10 to 11. That discount partly reflects Novo’s loss of U.S. market share and the uneven history of its pipeline. But the data Novo presented at ObesityWeek 2026 in Washington this weekend makes a reasonable case that investors have overcorrected.

What the Science Actually Said

At ObesityWeek, results from the Phase 3b REDEFINE 9 trial, simultaneously published in The Lancet Diabetes & Endocrinology, showed that after 68 weeks, CagriSema produced roughly ~21% average weight loss on the efficacy estimand at the lower-dose level, versus a mid-single-digit loss on placebo depending on estimand. Critically, REDEFINE 9 is the first Phase 3 trial for weight management to evaluate CagriSema at doses lower than the maximum dose studied in the REDEFINE program, 2.4 mg / 2.4 mg, specifically 1.0 mg / 1.0 mg and 1.7 mg / 1.7 mg. Getting ~21% weight loss from a sub-maximum dose matters commercially. It suggests a dosing ladder with room to push further, and it expands the addressable patient population to those who tolerate lower doses.

Post hoc analyses from REDEFINE 1 showed that 67.8% of CagriSema-treated participants were early responders, defined as losing at least 5% of body weight by week eight, and that group went on to achieve a mean 25.4% weight loss by week 68. Early response within eight weeks is a clinically useful marker, since physicians treating obesity need to know quickly whether a drug is working for a given patient.

Then there is the bone question, which separates Novo’s clinical argument from Lilly’s entirely. On November 16, Novo presented research exploring biomarkers and post hoc analyses suggesting its amylin-based weight loss therapies may help preserve aspects of bone health during significant weight reduction. In a post hoc DXA substudy of 252 REDEFINE 1 participants, bone mineral density decreased with CagriSema, as expected with substantial weight loss, but remained within the normal range for age and sex at week 68. Novo also pointed to findings in small human studies in which dual amylin and calcitonin receptor agonists were associated with suppression of a biomarker of bone resorption, supporting further study of dual amylin and calcitonin receptor agonism during weight loss. GLP-1 drugs broadly have faced scrutiny over lean mass loss. A therapy that addresses bone density concerns offers a differentiated safety profile.

On the Wegovy side, the SIGNAL study tracked 26,213 adults on injectable semaglutide and found food noise scores fell by 0.42 points at one month and 0.72 points at six months. In OCTANE, adults starting oral semaglutide lowered food noise scores by roughly 25% over three months, with 86.4% reporting at least one improvement. These are real-world numbers from a large telehealth dataset, not a controlled trial, but they reinforce patient retention arguments for Wegovy ahead of CagriSema’s potential approval.

The Catalyst Clock

Novo Nordisk filed a New Drug Application with the FDA in December 2025 for CagriSema 2.4 mg / 2.4 mg and expects a decision in the fourth quarter of 2026. That means a ruling could arrive within weeks. Approval would hand Novo a second commercial obesity asset and reset the market share conversation. It is not guaranteed, but the Phase 3 data package is substantive.

Alongside the science, Novo’s capital return program is running steadily. As of November 13, the company had repurchased 43.7 million B shares at an average price of DKK 277.08, totaling DKK 12.1 billion under a programme that runs through February 2027. The company still expects to repurchase up to DKK 15 billion over the 12-month period. Active buybacks at a depressed share price are mechanically accretive. Novo is essentially crediting long-term holders while the market focuses elsewhere.

What Could Still Go Wrong

The risks are real. Lilly has been gaining U.S. share in GLP-1s as tirzepatide expands across diabetes and obesity, and Novo has had to defend its position. An FDA rejection, even with this data package, would extend that gap. CagriSema’s earlier head-to-head against tirzepatide in REDEFINE 4 did not meet its primary endpoint, and that remains a competitive shadow. NVO shares are down materially year to date. Momentum alone would not bring investors back.

The investment case for NVO over LLY is not momentum. It is valuation compression meeting a converging catalyst. A company trading around 11 times trailing earnings, buying back stock, and sitting days away from an FDA verdict on a drug that just produced roughly 21% weight loss at sub-maximum doses is not a broken story. It is a mispriced one, and that is a distinction worth making before the ruling lands.